BFRI (40) RKTO (44) ALLR (38) LPCN (37) ⌘ Pro Terminal →

Dare Bioscience Inc. (DARE) — RQD Stock Rating Cockpit

$0.68 +0.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Dare Bioscience Inc. (DARE) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $13.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DARE)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

42.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.68H: $4

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on DARE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 71.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

18/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like DARE

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DARE)

✓Walkthrough of DARE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DARE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.18%▲ RESISTANCE BREAKOUT

2026-10-30O $0.70H $0.70L $0.67C $0.68VOL 651.5K

RES: $0.56SUP: $0.62SMA50: $0.75SMA200: $1.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DARE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DARE Butterfly Map → + Track DARE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DARE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DARE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DARE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DARE)

Health Care Rank #523 of 1016 ⚔️ BFRI vs DARE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DARE vs. BFRI, RKTO, ALLR, LPCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dare Bioscience Inc. (DARE) ranks #523 by composite RQD confidence (44/100, grade D) and #867 by equity capitalization ($13.4M). Within this direct 5-issuer industry benchmark cohort, DARE leads on earnings valuation at N/A trailing P/E, while DARE leads on capital efficiency and profitability with -35.0% ROIC and 71.3% gross margin. DARE currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DARE ACTIVE Dare Bioscience Inc.	D	44/100	—	71.3%	-35.0%	+0.22%	$13.4M	Benchmark Subject
BFRI Biofrontera Inc.	D-	40/100	—	—	-35.0%	+5.09%	$13.8M	/bfri-vs-dare →
RKTO Rocket One Inc.	D	44/100	—	—	-35.0%	-4.96%	$12.8M	/rkto-vs-dare →
ALLR Allarity Therapeutics Inc.	D-	38/100	—	—	-35.0%	-6.32%	$14.2M	/allr-vs-dare →
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-dare →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401914

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dare Bioscience Inc. (DARE) reported GAAP revenue of $1.0M (+10429.4% vs. FY2024 revenue of $9.8K , and -63.3% cumulative change since FY2023) , GAAP net income of -$13.4M, operating cash flow of -$9.9M, and free cash flow of -$10.3M (-309.6% YoY). On the balance sheet, DARE closed FY2025 with $32.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$13.4M	-$9.9M	-$10.3M	$32.5M	—
FY2024 (FY)	2024-12-31	$9.8K	-$4.0M	$5.5M	$4.9M	$22.1M	—
FY2023 (FY)	2023-12-31	$2.8M	-$30.2M	-$38.9M	-$38.9M	—	—

3. DARE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DARE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Dare Bioscience Inc. (NASDAQ: DARE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.68 (+0.22% 1D, market cap $13.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DARE ranks #523 in composite RQD confidence.

How does DARE compare to BFRI and RKTO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DARE carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -35.0%. By comparison, BFRI (Biofrontera Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and RKTO (Rocket One Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M). Among the 5-stock peer group, DARE leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DARE?

Per DARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401914), Dare Bioscience Inc. generated $1.0M in revenue (+10429.4% YoY), -$13.4M in net income, and -$10.3M in free cash flow against $32.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DARE trading relative to its 50-day, 200-day, and 52-week technical levels?

DARE last traded at $0.68 (+0.22% on volume of 46,862 shares), positioning the stock -9.33% below its 50-day simple moving average ($0.75) and -56.96% below its 200-day simple moving average ($1.58). Across its 52-week range of $0.63 to $3.78, DARE sits at the 1.6% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.77).

DARE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell DARE stock right now?

Dare Bioscience Inc. (DARE) currently earns a Roarable Rating of D (Sell — SELL) with 44/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is DARE's 12-month price target and RQD AI Jury consensus?

DARE's 12-month base price target is $0.64 (range $0.5 to $3.97), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: DARE RQD Cockpit DARE 12M Forecast DARE Earnings & Move DARE Dividends & DRIP DARE Insiders & 13F DARE Whale Options DARE Profit Sankey DARE News & Why